1. T2DM patients with HF may benefit from SGLT2 inhibitor therapy
A CANVAS program analysis
All patients
Patients with a history of HF at baseline
Patients without a history of HF at baseline
Canagliflozin better
Placebo better
SGLT2: sodium glucose cotransporter 2; CANVAS: Canagliflozin Cardiovascular Assessment Study; HR: hazard ratio; LCL: lower confidence limit; UCL: upper confidence limit; CI: confidence interval; HF: heart failure; CV: cardiovascular; T2DM: type 2 diabetes mellitus
Radholm et al. Circulation 2018